Grey Wolf has assembled a broad and impressive team of professionals charged with realizing the therapeutic potential of ERAP inhibition. In particular, the company’s leadership includes highly-regarded industry executives with deep experience in operations, as well as successful track records in the discovery, development and commercialization of novel therapeutics.
Peter is Co-founder and Chief Executive Officer of Grey Wolf and has over 13 years of experience in biomedical research leading drug discovery projects in immuno-oncology, rare genetic diseases and neurodegeneration. In his most recent role at Vertex Pharmaceuticals, he led drug discovery projects, had responsibility for leading a number of target identification teams that led to multiple novel drug discovery projects and was involved in delivering clinical drug candidates. He also pioneered the development of complex neurological assays suitable for assessing the functional impact of optimized compounds.
Prior to Vertex, Peter was an MRC Research Fellow investigating the pathophysiology and underlying mechanisms of neurodegeneration and publishing multiple first and co-author publications. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.
Tom Lillie is Chief Medical Officer at Grey Wolf Therapeutics, a company focused on using ERAP inhibition to overcome resistance in immuno-oncology. Dr Lillie completed his undergraduate training at Brasenose College, University of Oxford, where he was awarded a first-class degree in pharmacology, cell biology and immunology, before earning his doctorate in cell biology from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honours distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.
Tom has led global, regional and affiliate medical teams, encompassing both early and late-stage clinical development and medical affairs functions. He has extensive experience in clinical research in phase 1 – phase 4, and in supporting regulatory, safety and reimbursement interactions. During his clinical and industry career he has specialised in oncology & haematology, but has also worked in cardiovascular, metabolic, vaccine, anti-infective and neurologic disease areas.
Andy Page is Chief Operating Officer and Chief Business Officer at Grey Wolf Therapeutics, where he is responsible for setting the commercial strategy to fuel the the continued growth trajectory for the company. He has a track record of building and transforming operations and culture, with over 25 years of strategic marketing and general management experience in the Life Science industry spanning biotech, big pharma and and medical technology and devices. After completing a combined honours degree in Pharmacology and Physiology at the University of Leeds, Andy developed his career in commercial operations and has led global, regional and affiliate teams in Europe, Asia Pacific, the Middle East and Africa. He gained senior level experiences at Johnson & Johnson (Janssen and J&J MedTech), Otsuka Pharmaceuticals and Beckley Psytech and concentrates on where and how to create and add value to businesses from pre-clinical development through to reimbursement, access and broad commercialisation. During his career he has worked across multiple therapeutic areas, and most recently as CEO and President of Otsuka Pharmaceutical Europe led the development and commercialisation of assets in oncology, neurology, psychiatry and renal disease areas.
The board of directors is comprised of seasoned industry executives with expertise that spans drug discovery and development, finance, operations, company creation, and M&A, among other relevant areas. The significant scientific expertise in the area of cancer shared by several board members is particularly valuable as the company advances its lead ERAP1 inhibitor as a next-generation immuno-oncology therapy.
Tracy is an Associate Director in the Life Sciences team at ICG focused on creating and building life science companies that address commercially attractive markets in diseases of high unmet medical need. Tracy has 20 years industry experience in venture capital, company creation and drug development. She’s spent the past 8 years of her career as an investor and was previously a Principal at Bridge Valley Ventures and an Associate at Epidarex Capital. Prior to that she worked in technology transfer at Edinburgh University and Cancer Research UK with a focus on company creation/spinout. Underpinning this is a background in drug discovery and development as a Project Manager at Quintiles and Fulcrum Pharma where she led several projects from pre-clinical to clinical development across a variety of therapeutic areas.
Tracy holds a BSc in Chemistry and an MBA from the University of Strathclyde, Glasgow.
Peter is Co-founder and Chief Executive Officer of Grey Wolf and has over 13 years of experience in biomedical research leading drug discovery projects in immuno-oncology, rare genetic diseases and neurodegeneration. In his most recent role at Vertex Pharmaceuticals, he led drug discovery projects, had responsibility for leading a number of target identification teams that led to multiple novel drug discovery projects and was involved in delivering clinical drug candidates. He also pioneered the development of complex neurological assays suitable for assessing the functional impact of optimized compounds.
Prior to Vertex, Peter was an MRC Research Fellow investigating the pathophysiology and underlying mechanisms of neurodegeneration and publishing multiple first and co-author publications. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.
Tom is a Co-Founder and Chairperson of Grey Wolf Therapeutics and brings over 25 years of experience in drug discovery, development and commercialization to the team. Grey Wolf Therapeutics was created and incubated within M:M Bio Limited (Molecule 2 Medicine), a U.K.-based biotechnology hub that leverages its unique ecosystem to build enduring, commercially orientated drug discovery and development companies. Tom is Co-Founder and Chairperson of M:M Bio and also Co-Founder and Executive Chairperson of two additional biotechnology companies that are part of the overall M:M Bio hub; ThirtyFiveBio and Pathios Therapeutics. His additional roles include Chair of Orbit Discovery and Venture Partner at Brandon Capital. Prior to his leadership positions within the M:M Bio hub, he was President and CEO of Spinifex Pharmaceuticals, a private VC backed US/Australian biotech company developing first in class treatments for chronic pain, devoid of central nervous system side-effects. Spinifex Pharmaceuticals was purchased by Novartis in 2015 for approximately US$700 million. Previous positions include Vice President of Drug Development at Starpharma Holdings Limited (Australia). He holds BSc (Hons) and PhD degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.
Raphaël joined the Life Sciences Team of Andera Partners (formerly Edmond de Rothschild Investment Partners) in 2001. Previously, he worked in Healthcare Corporate Finance at Goldman Sachs starting at Salomon Smith Barney. He worked also in the Finance Department of Health in London and in the finance department of General Healthcare in London, the private hospital group. Raphaël is a graduate of the Ecole des Hautes Etudes Commerciales and holds a postgraduate diploma in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris. Raphaël is a Director of Axonics, ReViral, MedDay Pharmaceuticals, Artios Pharma and Grey Wolf.
Brent joined Canaan in 1999 as a member of the Kauffman Fellows Program and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent’s current investments and board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, device maker for chronic back pain Relievant MedSystems, life sciences tool company Unchained Labs, and pain management developer Semnur. His previous companies include Dexcom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), AtheroMed (acquired by VOLC); Durata Therapeutics (DRTX), Data Sciences International (acquired by HBIO); Elevation Pharmaceuticals (acquired by DNPUF); and Spinifex (acquired by NVS). Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit. Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.
A medical doctor with a PhD in immunology, Dr Thierry Hercend has acquired more than 30 years of experience in the academic sector and the pharmaceutical industry in various therapeutic fields, including oncology and inflammatory diseases. Since 2006, Thierry has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Thierry was Vice President in charge of the therapeutic oncology sector for Aventis. From 1998 to 2002, Thierry was Vice President (Europe) for research at Vertex Pharmaceuticals. He entered the pharmaceutical industry in 1990 at Roussel-Uclaf as Director of Therapeutic Immunology and then Scientific Director of the Health Division. Before joining the industrial sector, Thierry was responsible for the Immuno-Hematology laboratory at Gustave Roussy Villejuif Institute, France ; director of the INSERM U333 unit dedicated to the immunology of tumors ; and professor of immunology at Université de Médecine-Paris XI, France. Thierry is the author of more than 120 publications in oncology, autoimmune diseases and transplantation.
Rabab Nasrallah, PhD is a Healthcare Investment Professional at Earlybird Venture Capital, investing in early-stage companies across digital health, medical devices, diagnostics, R&D platform technologies, and biopharma. Currently, Rabab is a board member of Grey Wolf Therapeutics and a board observer of ImCheck Therapeutics, Atlantic Therapeutics, Argá Medtech, and Priothera.
Before joining Earlybird, Rabab was the program manager at INCUBATE, a startup accelerator at the University of Sydney, Australia. With an extensive research background, Rabab has held roles in leading global research organizations in Australia and the UK, including The George Institute for Global Health, Lowy Cancer Research Centre, Cancer Research UK, and Cambridge University.
Rabab has received her PhD in regenerative medicine from UNSW Sydney and Cancer Research UK Manchester Institute. She has also completed a postdoctoral fellowship at the Babraham Institute in Cambridge, focusing on therapeutics in the immuno-oncology and auto-immune disease space.
Sally joined Oxford Science Enterprises in February 2021, bringing over 8 years of oncology-focused research experience from world-leading academic institutions.
She works on uncovering new opportunities across the Life Sciences and supports the creation of new biotech businesses as well as the management of the existing portfolio.
Sally was previously an Anderson Cancer Center Post-Doctoral Fellow at the Rockefeller University in New York where her research focused on genetic instability at the very earliest stages of cancer development. Prior to this, she completed a PhD at the Francis Crick Institute in London where she uncovered an important role for polypoid cells in driving cancer evolution.
Academic research that Sally has contributed to has been published in leading journals including Nature Genetics, Nature Communications and Cancer Discovery.
Sally has also studied corporate finance at NYU, and consulted for The Solution Lab.
Marie-Claire is a Partner on the Pfizer Ventures Team and an Executive Director in Emerging Science & Innovation at Pfizer. In her current role she is responsible for investing in early-stage biotech companies and supporting them in advancing emerging science to deliver new medicines to patients. She is on the Board of Directors for DEM Biopharma and Grey Wolf Therapeutics.
Marie-Claire holds a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She conducted postdoctoral work at Yale University and has spent 25 years at Pfizer holding various leadership positions supporting small molecule discovery. As part of her former responsibilities, Marie-Claire founded and led the Primary Pharmacology Group for 13 years during which time they were responsible for the identification of nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), and ten additional therapeutics that are currently in clinical trials. She has additional experience leading compound management, high throughput ADME, data support and management, genetically modified models, preclinical bioimaging and biobanking.
Marie-Claire was recognized as a PhRMA ‘We Work For Health’ Champion in 2018 and was a 2019 finalist for the CT Women of Innovation Award. She is active on multiple community non-profit boards and is the Executive Sponsor for the Pfizer Women’s Resource Group in CT.
Emma is a Senior Investment Manager in the British Patient Capital Direct Investments team, where she focuses on opportunities in the life sciences.
Emma joined the BPC team in September 2021 at the launch of Future Fund: Breakthrough and has led investments into companies spanning novel therapeutic modalities and technologies driving efficiencies in the life sciences sector. Previously, Emma spent three years investing in a broad array of life sciences companies for the Greater Manchester and Cheshire Life Sciences Fund managed by Catapult Ventures.
Emma also joined Fund Her North as a founding member with the goal of increasing access to finance for female entrepreneurs in the North of England and has a background in Neuroscience.